Cytokine Response to Subclinical Cytomegalovirus Reactivation as a Cause of Severe Fatigue in Women Undergoing Chemotherapy for Breast Cancer

2013 ◽  
Author(s):  
Ann Hill
Keyword(s):  
Breast Cancer ◽  
Cytokine Response ◽  
Cytomegalovirus Reactivation ◽  
Severe Fatigue

scholarly journals A Randomized, Controlled, Parallel-Group, Trial on the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments

2021 ◽  
Vol 20 ◽  
pp. 153473542098834
Author(s):  
Abdolazim Sedighi Pashaki ◽  
Kamal Mohammadian ◽  
Saeid Afshar ◽  
Mohammad Hadi Gholami ◽  
Abbas Moradi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Intervention Group ◽  
Chi Square ◽  
Significance Level ◽  
Severe Fatigue ◽  
Before And After ◽  
Brief Fatigue Inventory ◽  
Chi Square Test ◽  
Student’S T

Objective: Fatigue associated with malignant conditions and their treatments is a disabling condition. This trial assessed the anti-fatigue effects of melatonin coadministration during adjuvant treatment of patients with the breast cancer. Material and Methods: Patients with breast cancer were randomly assigned to receive melatonin or placebo during adjuvant chemotherapy and radiotherapy. Thirty-seven patients were randomly enrolled in each group. The mean ages of patients in the intervention and control groups were 50.47 ± 10.79 and 46.05 ± 10.55 years, respectively ( P = .223). The intervention group received oral melatonin (18 mg/day) from 1 week before until 1 month after the adjuvant radiotherapy. The level of fatigue was assessed before and after intervention using Brief Fatigue Inventory (BFI) in both groups. To analyze data, the Student’s t-test and the Chi-square test were used at a significance level of P ≤ .05. Results: The BFI score was similar before the intervention in both groups, however, after the intervention, it was significantly lower in the melatonin group ( P < .001). Moreover, the frequency of severe fatigue in the melatonin group was significantly lower than in the placebo group after intervention (42.1% vs 83.3%, P < .001). Conclusion: Coadministration of melatonin during adjuvant chemotherapy and radiotherapy of women with breast cancer decreased the levels of fatigue associated with the malignant condition and its treatments.

scholarly journals Relationship of fatigue with depressive symptoms and level of physical activity in women with breast cancer diagnosis

2020 ◽  
Vol 22 ◽  
Author(s):  
Luciana Beatriz Bosi Mendonça de Moura Matoso ◽  
Leonessa Boing ◽  
Thainá Korpalski ◽  
Mirella Dias ◽  
Jéssica Moratelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Depressive Symptoms ◽  
Clinical Information ◽  
Breast Cancer Diagnosis ◽  
Cross Sectional Study ◽  
Short Version ◽  
Cross Sectional ◽  
Oncology Research ◽  
Severe Fatigue

Abstract Breast cancer is the most frequent in women, resulting in fatigue and depressive symptoms as consequence of treatment, but physical activity can help in this process. The aim of this study was to investigate the relationship between fatigue, depressive symptoms and practice of physical activity of women with breast cancer during treatment or after cancer treatment. This is a cross-sectional study with 179 women (56.89 ± 9.4 years) from the Oncology Research Center - CEPON, using questionnaire on general and clinical information, fatigue (Piper Fatigue Scale) depressive symptoms (Beck Depression Inventory) and physical activity (IPAQ - short version). Women with moderate to severe fatigue underwent physiotherapy (p = 0.001) and women with no fatigue had minimum depressive symptoms (p ?0.001). Level of physical activity was not associated with fatigue, with most women being insufficiently active and women with mild fatigue had longer walking time than those without fatigue (p = 0.049). Women with depressive symptoms were almost three times more likely of having mild to severe fatigue and those who underwent physiotherapy were twice as likely of having mild to severe fatigue. Women with fatigue had greater presence of depressive symptoms. Professionals working in the field of oncology should recommend the practice of physical activity in order to minimize the side effects of treatment and observe depressive symptoms and fatigue in these women.

scholarly journals Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors

2016 ◽  
Vol 27 (6) ◽  
pp. 965-974 ◽  
Author(s):  
H.J.G. Abrahams ◽  
M.F.M. Gielissen ◽  
I.C. Schmits ◽  
C.A.H.H.V.M. Verhagen ◽  
M.M. Rovers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Breast Cancer Survivors ◽  
Meta Analysis ◽  
Breast Cancer Treatment ◽  
Severe Fatigue

Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.

1998 ◽  
Vol 16 (5) ◽  
pp. 1689-1696 ◽  
Author(s):  
J A Broeckel ◽  
P B Jacobsen ◽  
J Horton ◽  
L Balducci ◽  
G H Lyman
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Psychiatric Disorder ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Chemotherapy Treatment ◽  
Severe Fatigue ◽  
History Of ◽  
History Of Cancer

PURPOSE Clinical reports suggest that many breast cancer patients experience persistent fatigue as a long-term side effect of adjuvant chemotherapy treatment. To investigate this issue further, we examined the characteristics and correlates of fatigue in women who had completed adjuvant chemotherapy for breast cancer and in a comparison group of women with no history of cancer. PATIENTS AND METHODS Participants were 61 women with breast cancer who had completed chemotherapy an average of 471 days previously and 59 women with no history of cancer. All participants completed standardized self-report measures of fatigue, sleep quality, menopausal symptoms, and coping and were administered a structured clinical interview to identify current and past psychiatric disorder. RESULTS Compared with women with no history of cancer, former adjuvant chemotherapy patients reported more severe fatigue (P < .01) and worse quality of life because of fatigue (P < .05). More severe fatigue among patients was significantly (P < .05) related to poorer sleep quality, more menopausal symptoms, greater use of catastrophizing as a coping strategy, and current presence of a psychiatric disorder. CONCLUSION These findings support the view that many breast cancer patients experienced heightened fatigue after completion of adjuvant chemotherapy treatment. Results yield a profile of women who are at increased risk for heightened fatigue after chemotherapy and suggest ways to intervene clinically to prevent or reduce fatigue in this patient population.

Patient reported symptom severity in cancer survivors.

2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 143-143
Author(s):  
Kelly Bugos ◽  
Jessica Foran ◽  
Katrina Pose Sabati ◽  
Andre Valdez ◽  
Janis M. Petree ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Survivorship ◽  
Symptom Severity ◽  
Breast Cancer Survivors ◽  
Psychological Symptoms ◽  
Cancer Type ◽  
Memory Change ◽  
Severe Fatigue ◽  
Patient Reported

143 Background: At Stanford Health Care, patient-reported symptom severity is routinely assessed during cancer survivorship visits. Aim: Our objective is to identify the proportion of moderate to severe symptoms reported during first visit by patient group (breast cancer, lymphoma, allogeneic BMT recipients). Methods: Our cohort were unique patients evaluated in a cancer survivorship clinic between 9/1/15 and 8/31/16. Cohort patient report of presence and severity of 23 symptoms using a six-point Likert scale on a paper-based written instrument were collected and analyzed (0 = absent, 1-2 = mild, 3-4 = moderate, 5 = severe). Symptoms include fatigue, pain, constipation, diarrhea, uncontrolled loss of urine, limb swelling, shortness of breath, oral problems, trouble swallowing, muscle weakness, unusual sweating, ability to exercise, numbness in limbs, depression, fear, changes in sleep, body image, skin/hair, appetite, weight, sexual health, cognition and/or balance. Results: 337 unique patients (median age 50, female 64%) were a median of 140 days and mean of 851 days after treatment completion. Overall, the symptoms that have the highest responses in the moderate to severe range (score 3-5) are fatigue (31%), sleep change (23%), memory change (17%), depression (14%) and fear (19%). Breast cancer survivors had similar symptoms overall, but lymphoma survivors reported a higher rate of moderate to severe fatigue (49%), sleep change (38%), memory change (33%) and fear (29%), and the alloBMT group reported a higher rate of moderate to severe fatigue (39%), depression (20%) and fear (25%). Conclusions: Standard use of patient-reported symptom severity assessment shows a high prevalence of moderate to severe physical and psychological symptoms among patients seen in a cancer survivorship clinic. These findings can help focus management on the most prevalent and severe symptoms based on cancer type and time from treatment.

Sign in / Sign up

Export Citation Format

Share Document